dant glycoprotein present in alveolar lavage. The SP-A polypeptide consists of distinct domains which include an amino-terminal collagenous domain, a potential amphipathic helical region, and a carboxy-terminal lectin-like domain. In the human, a single, asparagine-linked oligosaccharide moiety is located in the carboxy-terminal domain (for review see Refs. 1 and 2). SP-A undergoes extensive posttranslational modification, which includes acetylation (3), sulfation (4) , hydroxylation of prolines (5) , and the addition of complex oligosaccharides (6) (7) (8) . The asparagine-linked oligosaccharide on SP-A is added as a high-mannose precursor that is trimmed by glucosidases and mannosidases before sialylation (6, 7, 9) . Lamellar body-rich fractions from type I1 cells of lung contain sialylated, mature SP-A isofonns that comigrate with SP-A isolated from pulmonary lavage (9, 10) . Although the function of SP-A is not known with certainty, SP-A enhances the biophysical properties of surfactant lipids obtained by organic solvent extraction of lung surfactant (1 1, 12) . SP-A organizes phospholipids in a calcium-dependent manner (13) , forming tubular myelin in the presence of surfactant protein B, calcium, and phospholipids (14) . SP-A enhances phospholipid uptake and inhibits phospholipid secretion from type I1 epithelial cells in vitro (1 5-1 7) . Expression of SP-A increases in association with the maturation of type I1 epithelial cells and appears in increasing concentrations in amniotic fluid with advancing gestation. The measurement of SP-A in amniotic fluid has been used to predict pulmonary maturity in premature infants and therefore their risk for respiratory distress syndrome (1 8, 19) . Surfactant containing human SP-A has also been used for treatment of respiratory distress syndrome in premature infants (20) . Recombinant SP-A has been considered as an additive in surfactant replacement preparations. Thus, SP-A is potentially useful in diagnosis and treatment of surfactant-deficient disorders, making clarification of its structure and antigenicity clinically relevant. In the present work, we demonstrate that SP-A shares strong antigenic determinants with a major blood group antigen.
MATERIALS AND METHODS
Purification of SP-A. SP-A was purified from pooled alveolar lavage surfactant obtained from human cadavers, from amniotic fluid obtained at cesarean section at term, or from alveolar lavage from patients with alveolar proteinosis using previously described methods of Ross et al. (2 1,22) , who used etherlethano1 extraction and isoelectric focusing. SP-A used in immunoblot studies with the polyclonal antibodies and MAb was purified from a single patient with alveolar proteinosis, by the methods described by Haagsman et al. (23) . This patient is blood group A, Rh(-). SP-A migrated primarily with M, = 30 000-36 000, M, = 60 000-70 000, and larger by SDS-PAGE with a pI of pH 3.8-4.8 assessed 365 by 2D-IEF-SDS-PAGE (24) . Purity of the SP-A preparations was assessed by sensitive silver staining after SDS-PAGE. SP-A was also obtained from alveolar lavage surfactant from normal adults who were blood group A and blood group B.
Endoglycosidase F, neurarninidase, and collagenase digestion.
Purified SP-A was heated (10O0C, 3 min) in 2.5% NP-40, 5% Pmercaptoethanol, 1 % SDS and dissolved in four volumes of O. 1 M sodium phosphate (pH 6. l), 20 mM EDTA, 5 pg/mL leupeptin, 5 pg/mL pepstatin A, and endoglycosidase-F (8.8 U/mL). SP-A was incubated with endoglycosidase-F at 37°C for 16 h. SP-A was treated with bacterial collagenase after heating to 100°C for 3 min in 5 mM sodium N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (pH 7.2), 1% NP-40. The sample was diluted in an equal volume of 0.1 M Tris HC1 (pH 7.3), 0.1 M NaCl, 1 mM MgSO.,, 1 mM CaCI2, 5 pg/mL leupeptin, 5 pg/mL pepstatin A, and bacterial collagenase (25 U/mL) overnight at 37°C. MAb production. SP-A was purified from pooled alveolar lavage samples from human cadavers or amniotic fluid and used for immunization of mice. Antibody production was assessed by ELISA, and sensitized animals were used for production of MAb by use of the general methodology described by Galfrey and Milstein (25) using SP-A samples pooled from a number of individuals. Cells producing anti-SP-A were dilution-subcloned to homogeneity and injected into nude mice for production of ascites fluid. The antibody isotypes of both MAb-8 and MAb-3 were identified as IgG,-K.
Polyclonal antibodies. Approximately 0.5 mg of purified SP-A (pooled samples) was injected intradermally into both rabbits and goats in Freund's complete adjuvant at approximately 2-wk intervals until the sera were sufficiently reactive with SP-A by direct ELISA assay. Sera were then collected by cardiocentesis or by exsanguination. The Ig was purified by ammonium sulfate precipitation. A sandwich ELISA using the goat and rabbit antisera was established as previously described (18) . Rabbit polyclonal antisera, hSP-A, was used directly or after extensive adsorption with A blood group human erythrocytes.
Electrophoresis and irnrnunoblot analysis. Proteins were separated by SDS-PAGE and 2D-IEF-SDS-PAGE as previously described (6, 7) . Proteins were transferred to nitrocellulose for immunoblot analysis as described by Towbin et al. (26) . The nitrocellulose was then incubated overnight with the primary antibodies, and binding was assessed by incubation with peroxidase-conjugated goat anti-rabbit Ig for 4-6 h. The immunoperoxidase reaction was developed using 4-chloro-napthol and H202 as substrate.
Blood group antibodies. MAb and polyclonal blood group antibodies or antisera were obtained from the Hoxworth Blood Center, University of Cincinnati College of Medicine. The following antisera or antibodies were used. Anti A: murine MAb A-I, A-2, and A-3; murine monoclonal blend GA-00 1, GA-002, and Ort 1160; and human Ig Coop-260 and GAM A28-1. Anti B: murine MAb B-1 and B-2; murine monoclonal blend GB-00 1, GB-002,ORT-85023, and ORT-5 120; and human Ig ORT-BB436. Anti AB reagents consisted of murine monoclonal blend GAB-001 and GAB-002 and human Ig BCA-4-48 and IMM-5P319.
Tissue samples. Samples were obtained from tissue blocks stored in paraffin or newly prepared blocks from a variety of patients, including children dying from nonpulmonary causes, children and adults with cystic fibrosis, adults with chronic lung disease, and infants with respiratory distress syndrome and bronchopulmonary dysplasia. One to 12 tissues from 40 subjects were examined, including lung, trachea, esophagus, stomach, duodenum, ileum, jejunum, large intestine, liver, kidney, salivary gland, pancreas, uterus, cervix, prostate, and epididymis. Some specimens were derived from a collection of lung and tracheal tissues obtained at autopsy from abortuses and premature and term newborn infants. Additional tissues were obtained from the autopsy files of the Departments of Pathology of Vanderbilt Medical Center, Cincinnati Children's Hospital and Chicago Memorial Hospital. Tissues were obtained with parental consent, and these studies were approved by the Committee for the Protection of Human Subjects of Vanderbilt University Medical Center. In general, tissues were fixed in 10% phosphate-buffered formalin, processed, and embedded in paraffin. Sections, 3-5 pm in thickness, were cut from each block and mounted on aminoalkylsilane-coated slides.
Zmmunohistochernistry. Immunoreactivity of human polyclonal antiserum (anti-hSP-A) and MAb-8 was localized using the unlabeled antibody peroxidase-antiperoxidase method of Sternberger (27) . When using anti-hSP-A, sections were washed in a solution of 0.3% hydrogen peroxide in methanol for 30 min, then hydrated and preincubated with 10% normal swine serum in PBS (pH 7.2). After blotting, sections were incubated overnight at room temperature with anti-hSP-A (1:500). Nonspecific immunostaining was assessed in each case by substitution of nonimmune rabbit serum (1:500; Dako Corp., Santa Barbara, CA) for the primary antiserum. Sections were then incubated sequentially with swine antirabbit Ig (1:20; Dako Corp.) and rabbit peroxidase-antiperoxidase (1:50; Dako Corp.) for 30 min each. All incubations were followed by two 10-min washes in PBS. The tissues were subsequently exposed to 3'3-diaminobenzidene (DAB; Sigma Chemical Co., St. Louis, MO), 0.5 mg/mL in 0.05 M Tris-Cl (pH 7.6) containing 0.005% hydrogen peroxide. Slides were counterstained with hematoxylin.
Using MAb-8, sections were first quenched with 0.3% hydrogen peroxide in methanol, then hydrated and pretreated with 10% normal swine serum for 30 min followed by incubation with the primary antibody, MAb-8 (1:750), for 2 h at room temperature. After washing, sections were incubated with peroxidase-conjugated rabbit antimouse Ig (1:40) for 45 min. Sections received three 5-min washes in Tris-buffered saline (pH 7.6). Subsequently, sections were incubated 45 min with peroxidase-conjugated swine antirabbit Ig (1:40), then washed as above. The DAB was applied and the sections counterstained as in the procedure for polyclonal antibodies. Nonspecific immunostaining was assessed by substitution of an irrelevant antibody, mouse monoclonal antibombesin (Boehringer Mannheim Biochemicals, Indianapolis, IN), and purified mouse IgG (Sigma Chemical Co.) for the primary antiserum.
Ablation studies. Ablation of tissue staining with MAb-8 was canied out using washed blood group A red cells incubated with MAb-8 antiserum overnight at room temperature.
Agglutination of erythrocytes. Approximately 15 pL of A, B, or 0 human erythrocytes were added to microtiter wells containing 15 pL of antiserum or antibody. The microtiter plate was centrifuged 15 s at 1000 rpm and the plate gently agitated. Clumping was detected microscopically and scored according to standard blood typing procedures (28) . RESULTS SP-A purified from surfactant obtained from a patient with alveolar proteinosis [blood type A Rh(-)I migrated as heterogenous isoforms with M, = 30 000-36 000 (monomeric), 60 000-65 000 (dimeric), and larger; pI = 3.8-4.5 as assessed by 2D-IEF-SDS-PAGE or SDS-PAGE. The SP-A isoforms were recognized by rabbit (anti-hSP-A) and goat polyclonal antibodies (Fig. 1 ). Size and charge heterogeneity of SP-A was related in part to the presence of asparagine-linked carbohydrate and sialic acid, as previously reported (24) .
MAb-8. MAb were produced after immunization of mice with purified SP-A isolated from pooled samples of human amniotic fluid obtained at term or from alveolar lavage samples pooled from human cadavers at autopsy. Anti-hSP-A, MAb-8, was an IgG,-K isotype that reacted by ELISA and immunoblot with SP-A after SDS-PAGE or 2D-IEF-SDS-PAGE, identifying the monomeric and oligomeric SP-A isoforms (Fig. 2) . Reactivity was somewhat more active with the dimeric than monomeric forms detected in SP-A purified from patients with alveolar proteinosis.
MAB-3
Fig. 1. lmmunoblot of human SP-A from alveolar lavage of a blood group A patient with alveolar proteinosis. SP-A was purified as described in Materials and Methods, subjected to 2D-IEF-SDS-PAGE, and immunoblotted using rabbit hSP-A polyclonal antiserum. SP-A and its oligomers migrated with M, = 30 000-36 000,60 000-65 000, and larger, pI 3.8-4.5 (acidic side of the gel is to the left), detecting both glycosylated and nonglycosylated SP-A isoforms.
Reactivity of MAb-8 by immunoblot was not lost after neuraminidase (not shown) or endoglycosidase-F (Fig. 2) , which removed the asparagine-linked oligosaccharide from SP-A. Reactivity of MAb-8 was markedly decreased after treatment of SP-A with collagenase as assessed by immunoblot after SDS-PAGE (Fig. 2, lane i) . These findings are consistent with the reactivity of MAb-8 with an epitope located in the amino-terminal domain of SP-A, which is lost after collagenase digestion. Findings with MAb contrasted sharply with those using a distinct SP-A MAb, MAb-3. MAb-3, also an IgG,-K, reacted strongly to collagenasetreated SP-A, identifying the carbohydrate-containing or carboxy-terminal domain (M, = 20 000) (Fig. 2, lane e) . binding of MAb-3 was markedly decreased after removal of the asparaginelinked oligosaccharide with endoglycosidase-F. These findings are consistent with the binding of MAb-3 to an epitope dependent primarily upon the complex oligosaccharide located in the carboxy-terminal lectin-like domain at Asn'".
Immunohistochernical localization of SP-A. The intracellular localization of reactivity to anti-hSP-A was diffuse and, in blood group A patients, anti-hSP-A immunostained alveolar type I1 cells, Clara cells, bronchial and bronchiolar epithelium, and the nonmucous cells of tracheal and bronchial glands (Fig. 3 ). Cells of a wide variety of other secretory glands and epithelia, including lacrimal glands, Von Ebner's glands (tongue), esophageal glands, pyloric and fundic glands of the stomach (nonparietal cells), Brunner's glands and duodenal epithelium, Lieberkiihn's glands (throughout the small intestine), nonmucous cells and ducts of the submaxillary gland, acini and ducts of the pancreas, gall bladder and common bile ducts, intrahepatic bile ducts, eccrine sweat glands, collecting ducts and calyces of the kidney, epithelial cells of the prostate and epididymis, and uterine and cervical glands were also immunostained with anti-hSP-A. Unstained were brain, pituitary, parathyroid, thyroid and adrenal, thymus, ovary or testis, spleen, lymph nodes, and cardiac, striated, or smooth muscle. With the exception of kidney, pancreas, Brunner's glands, and eccrine sweat glands in patients with blood groups 0 or B, anti-hSP-A immunostained the same tissues as in blood group A patients (Fig. 4) . Nonimmune rabbit serum substituted for the primary antibody failed to immunostain epithelial cells stained by anti-hSP-A. Immunostaining of tissues with anti-hSP-A was ablated by incubation with hSP-A (Fig. 5) .
Immunostaining with MAb-8 was widespread and characteristic but present only in tissues from individuals who were blood group A or AB. Tracheal, bronchial, and bronchiolar columnar lining cells of the lung were specifically immunostained heavily in the supranuclear area, in the region of the Golgi apparatus (Fig. 6) . Alveolar type I1 cells, Clara cells, and macrophages were also immunostained (Figs. 7 and 8) . The same wide variety of secretory glands and epithelia immunostained with anti-hSP-A in blood group A or AB patients was stained with MAb-8 in this same supranuclear region. No immunostaining of any tissue with MAb-8 occurred in blood groups 0 or B patients (Fig. 9) .
Tissue staining with MAb-8 in blood group A or AB patients was ablated by incubation of MAb-8 antiserum with washed blood group A red cells (Fig. 10) . Neuroendocrine cells were heavily immunostained with the irrelevant MAb, mouse antibombesin. However, very faint immunostaining in the supranuclear region of some bronchial and tracheal epithelial cells and of cells of the fundic glands was detected in two blood group A 368 STAHLMAN ET AL patients with mouse anti-bombesin and purified mouse Ig-G when they were substituted for the primary antibody.
Reactivity of MAb-8 with A blood group erythrocytes.
Because of the marked blood group-specific staining of epithelial cells in secretory tissue observed with MAb-8, we assessed the effects of MAB-8 on blood group-dependent aggregation of erythrocytes. MAb-8 caused rapid agglutination of A and AB but not 0 or B erythrocytes (not shown). A variety of human secretions, including cervical and nasal secretions, sweat, breast milk, urine, duodenal contents, and saliva reacted with the SP-A polyclonal antibodies as assessed by ELISA (data not shown). Reactivity, although variable in amount, was detected in all of these secretions. Reactivity of the ELISA with salivary secretions from a blood group A individual was markedly decreased after adsorption of both goat and rabbit antisera with blood group A erythrocytes (data not shown).
Reactivity of SP-A with blood group antibodies.
A series of murine monoclonal blood group antibodies and immune sera (from individuals with high-titer alloimmune-antibodies) was tested by ELISA for reactivity against purified SP-A from an individual with blood type A. All blood group A reagents were highly reactive with blood group A SP-A as assessed by ELISA (not shown). Similarly, monoclonal and polyclonal blood group A+B reagents reacted strongly with this purified SP-A by ELISA assay. The murine MAb and human antisera generated against B blood group antigens (seven antibodies or antisera) were unreactive with the SP-A from this A blood group patient. Antiblood group B antibodies failed to react with SP-A from blood group B individuals (n = 4). Endoglycosidase-F treatment of SP-A resulted in the loss of binding of blood group MAb blend, GAB-00 1, demonstrating its reactivity to the asparagine-linked oligosaccharide moiety on SP-A (Fig. 1 I) .
Thus, at least two distinct antigenic epitopes are identified by MAb-8 and GAB-001 (Table 1) . To further characterize the epitopes recognized by MAb-8, SP-A (blood group A) was subjected to a p-elimination reaction to cleave ester-linked moieties from SP-A. Reactivity of SP-A to MAb-8 was lost after the 0-elimination reaction (Fig. 12) . Reactivity to MAb-3 (directed against the carboxy-terminal, asparagine-linked oligosaccharide of SP-A and sensitive to endoglycosidase-F) was unaltered by Pelimination, further distinguishing the two distinct carbohydratedependent epitopes on the SP-A molecule.
DISCUSSION
The observation that an MAb (MAb-8) generated against purified SP-A from a blood group A patient with alveolar proteinosis immunostained a wide variety of epithelial cells, including those of the lung, only in blood group A or AB patients led to the studies described. In contrast, these same tissues from patients with blood groups B or 0 failed to immunostain with MAb-8. This immunostaining with MAb-8 was ablated by incubation of the antibody with blood group A washed red cells, which the antibody also agglutinated. The present studies demonstrate that antibodies generated against purified SP-A react with the major blood group A antigenic epitopes shared by SP-A and A-specific antigenic sites present on erythrocytes and other tissues known to be rich in blood group antigens. Blood group A-specific MAb bound SP-A in a blood group A-specific manner; however, no such crossreactivity was observed between blood group B antibodies with SP-A from blood group B individuals. We conclude that SP-A contains blood group antigenic determinants, one of which is composed, at least in part, of an epitope dependent upon the asparagine-linked oligosaccharide located at Asn'" in the carboxy-terminal, lectin-like domain of SP-A. Evidence supporting a distinct blood group antigenic site, dependent upon an amino-terminal epitope, is provided by the characteristics of binding of anti-SP-A MAb-8, which is lost after collagenase digestion and after p-elimination, clearly distinguishing this epitope from that in the carboxy-terminal, asparaginelinked oligosaccharide. The presence of blood group antigenic sites on the SP-A molecule may have important implications for the clinical use of SP-A in surfactant replacement preparations and for the use of SP-A antibodies for quantitation and localization of SP-A in lung tissues or amniotic fluid.
All eight blood group A immuno-reagents reacted with purified SP-A from a blood group A patient with alveolar proteinosis. The antigenic site recognized by the group MAb blend GAB-00 I was dependent upon the asparagine-linked oligosaccharide located at Asnla7. The structure of the asparagine-linked oligosaccharide on SP-A is not known with certainty. Processing of SP-A includes the addition of the dolichol-mannose group (which is blocked by tunicamycin), subsequent trimming by glucosidases and mannosidases, and ultimately, the addition of sialic acid, which occurs late in the processing pathway (7). Nuclear magnetic resonance analysis of peptides derived from the M, = 30 000-35 000 or 60 000-70 000 D polypeptide isolated from alveolar proteinosis surfactant were described by Bhattacharyya et al. (29) . The asparagine-linked oligosaccharide on these SP-A isoforms consisted of branched, mannose-containing, complex oligosaccharides. Similar linkages are known to cany epitopes of the major blood group determinants (for review, see Refs. 30, 3 1).
The immunoblot analysis of the binding of MAb-8 was readily distinguished from that of GAB-00 1 and this binding is consistent with reactivity of MAb-8 with a distinct site on the SP-A molecule. Binding of MAb-8, as assessed by immunoblot after SDS-PAGE, was lost after collagenase treatment (the small peptides likely migrating through the gel during SDS-PAGE). This finding supports the presence of a blood group A-specific epitope distinct from that in the carboxy-terminal oligosaccharide recognized by GAB-001. Reactivity of the carboxy-terminal epitope with a distinct SP-A MAb (MAb-8) was maintained after collagenase digestion, which identified the predicted M, = 20 000 glycosylated, noncollagenous fragment. The finding that MAb-8 bound endoglycosidase-F-treated SP-A is consistent with the binding of MAb-8 to a site distinct from the carboxy-terminal, asparaginelinked oligosaccharide. P-Elimination ablated the MAb-8 antigenic determinant on SP-A under conditions in which binding of MAb-3 (to the Asn-linked epitope) was maintained. The findings with MAb-8 are consistent with its binding to a blood group-specific antigenic site distinct from the asparagine-linked, oligosaccharide-dependent site(s) recognized by either MAb-3 or GAB-00 1, although the precise structure of this epitope remains to be clarified.
ABO blood group antigens are specified by terminal carbohydrate moieties added sequentially to a carbohydrate core. The A, B, and H antigens are generated by glycosyl transferase activity, necessary for addition of the carbohydrate. The H antigen is generated by addition of a fucose residue to the peripheral galactose on the core. This structure is then modified by addition of N-acetylgalactosamine or galactosamine, in the case of type-A or type-B individuals, respectively. Type O individuals are characterized by possessing predominantly H antigen because of the absence of A-or B-type epitopes. The molecular basis for the ABO blood group specificity has been recently described by Yamamoto et al. (32) . ABH antigens are found in a variety of body fluids and tissues. The respiratory and gastrointestinal tract and associated glands are primary sites of expression of blood group antigens (30, 3 1, 33, 34) . The general tissue distribution of blood group antigens is identical to that of the SP-A antibodies described in the present study. Blood group antigens are present as glycoproteins, glycolipids, or as a free oligosaccharides. Although the antigenic determinant of each blood group antigen is identical in all structures, the core structures to which the terminal residues are attached are variable. The peripheral core consists of type I, 11, 111, and IV oligosaccharide structures, the subgroup being based upon carbohydrate linkage and the identity of the penultimate sugars. The inner core differs in regard to its length, degree of branching, and sugar composition, which changes during development and cell differentiation (34) (35) (36) . Blood group determinants associated with asparagine-linked glycoproteins are characteristically linked to a galactose 0-1-3N-acetylglucosamine (type I) or galactose 0-1 -4N-acetylglucosamine (type 11) peripheral core and a branched mannose inner core (30) . This core structure is consistent with the asparaginelinked carbohydrate structure of SP-A previously determined by nuclear magnetic resonance analysis (29) . However, type I1 peripheral cores are more common in ectodermal-and mesodermal-derived tissues than in endodermal derivatives and secretions, which are predominantly type I (galactose P-I-3N-acetylglucosamine) (30, 3 1) .
Although the ABH antigens were recognized 90 years ago, their biologic function remains unclear. The broad tissue distribution of ABH antigens and their prevalence in the evolutionary tree implicate their potential biologic importance. The possibility that ABH antigens act as attachment sites for microorganisms is supported by the observation that a variety of bacteria bind to complex carbohydrates (37, 38) . Orntoft et al. (39) have shown that patients with chronic cystitis have significantly less ABH antigen expression in epithelial cells of the urinary tract as compared with normal individuals. The potential role of SP-A in host defense has been suggested by recent studies demonstrating its role in opsonization of bacteria (40) . Whether the blood group antigenic sites on SP-A play a role in the mediation of lung defense remains to be clarified.
It is of clinical interest that circulating immune complexes recognizing whole human surfactant were detected previously in premature infants. Reactivity was demonstrated both in infants receiving and in those not receiving exogenous human surfactant containing surfactant protein (41) . Because these studies used pooled human surfactant, it is possible that isoimmune antibodies, recognizing major blood group antigens in surfactant or SP-A, were identified. The present study demonstrates blood groupspecific antigenic epitopes in the human pulmonary surfactant protein hSP-A. Immunochemical identification of SP-A in bio- logic samples and tissues may be influenced by the presence of blood group-dependent antigenic sites. This presents a potential problem in the interpretation of animal models used for studies of SP-A localization. A number of species may have either A antigen or Forssman antigen, which has considerable homology with the human A antigen, in red cells, tissue cells, or both. These species include chimpanzee, cattle, goat, sheep, horse, pig, dog, cat, mouse, rabbit, guinea pig, Chinese hamster, Syrian hamster, and chicken (42) . Similarly, the therapeutic use of SP-A for exogenous surfactant replacement therapy of infants and adults may be complicated by the presence of circulating blood group antibodies against the carbohydrate-dependent epitopes on SP-A.
